Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 trial Head-to-Head trial of ANX007 versus SYFOVRE to differentiate vision protection from slowing of lesion growth

Next Previous
Trial Profile

A phase 3 trial Head-to-Head trial of ANX007 versus SYFOVRE to differentiate vision protection from slowing of lesion growth

Status: Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ANX 007 (Primary) ; Pegcetacoplan
  • Indications Dry age-related macular degeneration
  • Focus Registrational; Therapeutic Use
  • Acronyms ARROW
  • Sponsors Annexon

Most Recent Events

  • 05 Aug 2024 Status changed from planning to not yet recruiting.
  • 26 Mar 2024 According to an Annexon Biosciences media release, pivotal Phase 3 head-to-head ARROW trial vs. SYFOVRE (pegcetacoplan injection) planned to initiate in the second half of 2024.
  • 26 Dec 2023 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top